Alnylam Pharmaceuticals, Inc. (ALNY)
NASDAQ: ALNY · Real-Time Price · USD
453.97
-5.61 (-1.22%)
Oct 8, 2025, 10:28 AM EDT - Market open
Alnylam Pharmaceuticals Stock Forecast
Stock Price Forecast
The 28 analysts that cover Alnylam Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $448.97, which forecasts a -1.10% decrease in the stock price over the next year. The lowest target is $220 and the highest is $583.
Price Target: $448.97 (-1.10%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Alnylam Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 | Oct '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 11 | 11 | 13 | 13 | 14 | 14 |
| Buy | 9 | 8 | 9 | 10 | 11 | 11 |
| Hold | 3 | 3 | 3 | 4 | 4 | 4 |
| Sell | 1 | 1 | 1 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 24 | 23 | 26 | 27 | 29 | 29 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Morgan Stanley | Morgan Stanley | Hold Maintains $405 → $475 | Hold | Maintains | $405 → $475 | +4.63% | Oct 6, 2025 |
| Stifel | Stifel | Strong Buy Maintains $441 → $495 | Strong Buy | Maintains | $441 → $495 | +9.04% | Oct 6, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $435 → $500 | Buy | Maintains | $435 → $500 | +10.14% | Sep 19, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $453 → $520 | Strong Buy | Maintains | $453 → $520 | +14.55% | Sep 17, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Maintains $504 → $566 | Strong Buy | Maintains | $504 → $566 | +24.68% | Sep 16, 2025 |
Financial Forecast
Revenue This Year
3.59B
from 2.25B
Increased by 59.55%
Revenue Next Year
5.05B
from 3.59B
Increased by 40.90%
EPS This Year
1.16
from -2.18
EPS Next Year
5.30
from 1.16
Increased by 355.93%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 4.0B | 8.0B | |||
| Avg | 3.6B | 5.1B | |||
| Low | 3.2B | 4.1B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 79.3% | 122.7% | |||
| Avg | 59.5% | 40.9% | |||
| Low | 44.5% | 13.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 3.22 | 13.91 | |||
| Avg | 1.16 | 5.30 | |||
| Low | -1.11 | 0.12 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | 1,095.8% | |||
| Avg | - | 355.9% | |||
| Low | - | -89.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.